Type of information: Development agreement
Company: Ionis Pharmaceuticals (USA - CA) Roche (Switzerland)
Therapeutic area: Ophtalmological diseases
Type agreement: development
- antisense drug. IONIS-FB-LRx is an antisense drug using Ionis' advanced LIgand Conjugated Antisense (LICA) technology. This compound reduces the production of FB, a key protein in the complement innate immune system. FB is predominately produced in the liver and circulates throughout the vascular system, including vessels in the eye and kidney. This complement protein plays a pivotal role in an innate immunogenic cascade that, when overactivated, has been associated with the development of several complement-mediated diseases, including dry AMD.
Disease: complement-mediated diseases including geographic atrophy
- • On October 10, 2018, Ionis Pharmaceuticals announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis' leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). A Phase 2 study in patients with GA is planned to begin in early 2019.
- In a Phase 1 study in 54 healthy volunteers IONIS-FB-LRx reduced plasma FB and was safe and well tolerated.
- Under this new collaboration, Ionis is responsible for conducting a Phase 2 study in patients with dry AMD and exploring the drug in a rare severe renal indication. Roche has the option to license IONIS-FB-LRx at the completion of the studies. Upon licensing, Roche will be responsible for all global development and commercialization activities.
- This new agreement builds upon previous relationship with Roche on IONIS-HTTRx (RG6042), an antisense drug for the treatment of people with Huntington's disease
- Under this new collaboration with Roche, Ionis will receive a $75 million upfront payment. In addition, Ionis is eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis also has the potential to receive tiered royalties that range from the high teens to twenty percent on sales from the product when commercialized.